比较分析已获 FDA 批准的药物在人肺细胞中抗 SARS-CoV-2 的疗效。
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
机构信息
Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, Korea.
CEO Office, Institut Pasteur Korea, Seongnam, Korea.
出版信息
J Med Virol. 2021 Mar;93(3):1403-1408. doi: 10.1002/jmv.26397. Epub 2020 Aug 16.
Abstract
Drug repositioning represents an effective way to control the current COVID-19 pandemic. Previously, we identified 24 FDA-approved drugs which exhibited substantial antiviral effect against severe acute respiratory syndrome coronavirus 2 in Vero cells. Since antiviral efficacy could be altered in different cell lines, we developed an antiviral screening assay with human lung cells, which is more appropriate than Vero cell. The comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells (IC = 0.0022 µM).
摘要
药物重定位是控制当前 COVID-19 大流行的有效方法。此前，我们在 Vero 细胞中鉴定出 24 种对严重急性呼吸综合征冠状病毒 2 具有显著抗病毒作用的 FDA 批准药物。由于抗病毒功效在不同细胞系中可能发生变化，因此我们开发了一种使用人肺细胞的抗病毒筛选测定法，比 Vero 细胞更合适。抗病毒活性的比较分析表明，那法莫司他是在人肺细胞中最有效的药物（IC = 0.0022 µM）。
相似文献
1
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells.
J Med Virol. 2021 Mar;93(3):1403-1408. doi: 10.1002/jmv.26397. Epub 2020 Aug 16.
2
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
J Virol. 2021 Oct 13;95(21):e0097521. doi: 10.1128/JVI.00975-21. Epub 2021 Aug 18.
3
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Pharmacol Res. 2020 Sep;159:104960. doi: 10.1016/j.phrs.2020.104960. Epub 2020 May 28.
4
iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
FEBS Open Bio. 2021 May;11(5):1452-1464. doi: 10.1002/2211-5463.13153. Epub 2021 Apr 6.
5
Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
Int J Antimicrob Agents. 2021 Mar;57(3):106274. doi: 10.1016/j.ijantimicag.2020.106274. Epub 2020 Dec 30.
6
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
7
Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches.
Biochem Biophys Res Commun. 2021 Jan 29;538:137-144. doi: 10.1016/j.bbrc.2020.10.094. Epub 2020 Nov 20.
8
Identifying FDA-approved drugs with multimodal properties against COVID-19 using a data-driven approach and a lung organoid model of SARS-CoV-2 entry.
Mol Med. 2021 Sep 9;27(1):105. doi: 10.1186/s10020-021-00356-6.
9
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2105815118.
10
Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2.
J Microbiol Biotechnol. 2020 Dec 28;30(12):1843-1853. doi: 10.4014/jmb.2009.09009.
引用本文的文献
1
From N-0385 to N-0920: Unveiling a Host-Directed Protease Inhibitor with Picomolar Antiviral Efficacy against Prevalent SARS-CoV-2 Variants.
J Med Chem. 2025 Apr 10;68(7):7119-7136. doi: 10.1021/acs.jmedchem.4c02468. Epub 2025 Mar 31.
2
PBPK-led assessment of antimalarial drugs as candidates for Covid-19: Simulating concentrations at the site of action to inform repurposing strategies.
Clin Transl Sci. 2024 Jul;17(7):e13865. doi: 10.1111/cts.13865.
3
Fuzzy optimization for identifying antiviral targets for treating SARS-CoV-2 infection in the heart.
BMC Bioinformatics. 2023 Sep 27;24(1):364. doi: 10.1186/s12859-023-05487-7.
4
Cell-specific genome-scale metabolic modeling of SARS-CoV-2-infected lung to identify antiviral enzymes.
FEBS Open Bio. 2023 Dec;13(12):2172-2186. doi: 10.1002/2211-5463.13710. Epub 2023 Sep 30.
5
Studying Dynamical Characteristics of Oxygen Saturation Variability Signals Using Haar Wavelet.
Healthcare (Basel). 2023 Aug 13;11(16):2280. doi: 10.3390/healthcare11162280.
6
Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections.
AAPS Open. 2023;9(1):9. doi: 10.1186/s41120-023-00072-x. Epub 2023 Apr 14.
7
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
Biomed Pharmacother. 2023 Jun;162:114614. doi: 10.1016/j.biopha.2023.114614. Epub 2023 Mar 28.
8
Discovery of 2-aminoquinolone acid derivatives as potent inhibitors of SARS-CoV-2.
Bioorg Med Chem Lett. 2023 Apr 1;85:129214. doi: 10.1016/j.bmcl.2023.129214. Epub 2023 Mar 2.
9
Glycogen Synthase Kinase-3 Interaction Domain Enhances Phosphorylation of SARS-CoV-2 Nucleocapsid Protein.
Mol Cells. 2022 Dec 31;45(12):911-922. doi: 10.14348/molcells.2022.0130. Epub 2022 Dec 19.
10
Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics.
Mol Aspects Med. 2023 Jun;91:101151. doi: 10.1016/j.mam.2022.101151. Epub 2022 Oct 28.
本文引用的文献
1
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
Cell Rep. 2020 Jul 21;32(3):107940. doi: 10.1016/j.celrep.2020.107940. Epub 2020 Jul 7.
2
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
3
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Viruses. 2020 Jun 10;12(6):629. doi: 10.3390/v12060629.
4
Three cases of treatment with nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy.
Int J Infect Dis. 2020 Jul;96:500-502. doi: 10.1016/j.ijid.2020.05.072. Epub 2020 May 26.
5
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
N Engl J Med. 2020 Jun 18;382(25):2411-2418. doi: 10.1056/NEJMoa2012410. Epub 2020 May 7.
6
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00819-20.
7
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
JAMA Netw Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
8
Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.
Circulation. 2020 Jul 14;142(2):184-186. doi: 10.1161/CIRCULATIONAHA.120.047430. Epub 2020 Apr 24.
9
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00754-20.
10
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
Zotero 插件